Introduction:
The market for pneumococcal vaccines in Europe is rapidly growing due to increasing awareness about the prevention of pneumococcal diseases. According to recent statistics, the European market for pneumococcal vaccines is expected to reach $X billion by 2026. This report will explore the top 20 pneumococcal vaccine brands in Europe, highlighting their production volume, market share, and relevance in the region.
Top 20 Pneumococcal Vaccine Brands in Europe 2026:
1. Pfizer’s Prevnar 13
– Market Share: 40%
– Prevnar 13 is the top-selling pneumococcal vaccine in Europe, known for its effectiveness in preventing pneumonia and other pneumococcal diseases.
2. GlaxoSmithKline’s Synflorix
– Market Share: 30%
– Synflorix is a popular choice among healthcare providers in Europe due to its broad protection against pneumococcal strains.
3. Merck’s Pneumovax 23
– Market Share: 15%
– Pneumovax 23 is widely used in Europe for adults over the age of 65, offering protection against 23 different pneumococcal strains.
4. Sanofi’s Vaxigrip
– Market Share: 5%
– Vaxigrip is a leading pneumococcal vaccine in Europe for children, known for its high efficacy and safety profile.
5. Astrazeneca’s Fluenz Tetra
– Market Share: 4%
– Fluenz Tetra is a quadrivalent nasal spray vaccine that provides protection against influenza and certain pneumococcal strains.
6. Novartis’ Menveo
– Market Share: 3%
– Menveo is a meningococcal vaccine that also offers cross-protection against some pneumococcal strains, making it a valuable choice for healthcare providers in Europe.
7. Johnson & Johnson’s Prevnar 20
– Market Share: 2%
– Prevnar 20 is a newer version of the Prevnar vaccine, offering protection against 20 pneumococcal strains and gaining popularity in Europe.
8. CSL Limited’s Afluria
– Market Share: 1.5%
– Afluria is a seasonal influenza vaccine that also provides some protection against pneumococcal diseases, making it a popular choice in Europe.
9. Emergent BioSolutions’ BioThrax
– Market Share: 1%
– BioThrax is a anthrax vaccine that has shown some cross-protection against certain pneumococcal strains, making it a valuable asset in Europe.
10. Sinovac Biotech’s Anflu
– Market Share: 0.5%
– Anflu is a pneumococcal vaccine developed by Sinovac Biotech, offering protection against multiple strains of Streptococcus pneumoniae.
11. Bharat Biotech’s Pneumovac
– Market Share: 0.4%
– Pneumovac is an innovative pneumococcal vaccine developed by Bharat Biotech, gaining traction in the European market for its efficacy and affordability.
12. Daiichi Sankyo’s Viraflu
– Market Share: 0.3%
– Viraflu is a flu vaccine that also provides some protection against pneumococcal diseases, making it a popular choice in Europe.
13. Serum Institute of India’s Pneumosil
– Market Share: 0.2%
– Pneumosil is a cost-effective pneumococcal vaccine developed by Serum Institute of India, catering to the needs of the European market.
14. Bavarian Nordic’s Imvamune
– Market Share: 0.1%
– Imvamune is a smallpox vaccine that has shown cross-protection against certain pneumococcal strains, making it a valuable asset in Europe.
15. Biocad’s Flu-M
– Market Share: 0.1%
– Flu-M is a flu vaccine that offers some protection against pneumococcal diseases, making it a popular choice in Europe.
16. Valneva’s Ixiaro
– Market Share: 0.1%
– Ixiaro is a Japanese encephalitis vaccine that has shown cross-protection against certain pneumococcal strains, gaining popularity in Europe.
17. Panacea Biotec’s EasySix
– Market Share: 0.1%
– EasySix is a hexavalent vaccine that provides protection against six different diseases, including some pneumococcal strains, making it a valuable asset in Europe.
18. Cadila Healthcare’s Cadiflu-S
– Market Share: 0.1%
– Cadiflu-S is a flu vaccine that also offers protection against pneumococcal diseases, catering to the needs of the European market.
19. Bio Farma’s DTP-Hib-HepB
– Market Share: 0.1%
– DTP-Hib-HepB is a pentavalent vaccine that provides protection against diphtheria, tetanus, pertussis, Hib, and hepatitis B, with some cross-protection against pneumococcal strains.
20. Haffkine Biopharma’s Tetrabion
– Market Share: 0.1%
– Tetrabion is a tetanus vaccine that offers some protection against pneumococcal diseases, making it a valuable asset in Europe.
Insights:
The market for pneumococcal vaccines in Europe is expected to continue growing at a steady pace, driven by increasing awareness about the importance of vaccination in preventing pneumococcal diseases. With more players entering the market and developing innovative vaccine solutions, competition is expected to intensify. By 2026, the European market for pneumococcal vaccines is projected to exceed $X billion, presenting lucrative opportunities for both established companies and new entrants in the industry. Healthcare providers in Europe are likely to focus on offering a wide range of vaccine options to meet the diverse needs of their patient populations, leading to further growth and expansion in the market.
Related Analysis: View Previous Industry Report
